MedTrace Logo

Effect of OC459 on the Response to Rhinovirus Challenge in Asthma

NCT02660489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-02-26

Study results available
· View outcomes & findings →

Summary

The aim of this study is to assess the effectiveness of a CRTH2 receptor antagonist, OC459, in preventing or attenuating the worsening of asthma symptoms during rhinovirus infection. The study is a double blind, randomised trial in which half the subjects will receive OC459 and the other half placebo, before being inoculated with rhinovirus, that would normally induce a worsening of asthma symptoms i.e. an exacerbation.

Conditions

  • Asthma
  • Rhinovirus
  • Picornaviridae Infections
  • Common Cold

Interventions

DRUG

OC459

DRUG

Placebo

OTHER

Rhinovirus

Inoculation with rhinovirus serotype 16

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • Atopix Therapeutics, Ltd.

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sebastian L Johnston, MBBS PhD · National Heart & Lung Institute, Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660489 on ClinicalTrials.gov